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Abstract
Genetic background may play an important role in the process of SARS-CoV infection and SARS development. We found
several proteins that could interact with the nucleocapsid protein of the SARS coronavirus (SARS-CoV). a-2-Heremans-
Schmid Glycoprotein (AHSG), which is required for macrophage deactivation by endogenous cations, is associated with
inflammatory regulation. Cytochrome P450 Family 3A (CYP4F3A) is an v-oxidase that inactivates Leukotriene B4 (LTB4) in
human neutrophils and the liver. We investigated the association between the polymorphisms of these two inflammation-
associated genes and SARS development. The linkage disequilibrium (LD) maps of these two genes were built with
Haploview using data on CHB+JPT (version 2) from the HapMap. A total of ten tag SNPs were selected and genotyped. In
the Guangzhou cohort study, after adjusting for age and sex, two AHSG SNPs and one CYP4F3 SNP were found to be
associated with SARS susceptibility: rs2248690 (adjusted odds ratio [AOR] 2.42; 95% confidence interval [CI] 1.30-4.51);
rs4917 (AOR 1.84; 95% CI 1.02-3.34); and rs3794987 (AOR 2.01; 95% CI 1.10–3.68). To further validate the association, the ten
tag SNPs were genotyped in the Beijing cohort. After adjusting for age and sex, only rs2248690 (AOR, 1.63; 95% CI, 1.30–
2.04) was found to be associated with SARS susceptibility. The combined analysis of the two studies confirmed tag SNP
rs2248690 in AHSG as a susceptibility variant (AOR 1.70; 95% CI 1.37–2.09). The statistical analysis of the rs2248690 genotype
data among the patients and healthy controls in the HCW cohort, who were all similarly exposed to the SARS virus, also
supported the findings. Further, the SNP rs2248690 affected the transcriptional activity of the AHSG promoter and thus
regulated the AHSG serum level. Therefore, our study has demonstrated that the AA genotype of rs2268690, which leads to
a higher AHSG serum concentration, was significantly associated with protection against SARS development.
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Introduction
Severe acute respiratory syndrome (SARS) is an acute
respiratory disease resulting from the infection of a previously
undescribed coronavirus (SARS-CoV) that spreads through
airborne transmission [1–3]. Rapid transmission, high infectivity
and unpredictable clinical progression with a fatality ratio of
approximately 9.6% made SARS a global threat in 2003.
However, the pathogenesis of this infectious agent is still not fully
understood. Asymptomatic and mildly symptomatic SARS-CoV
infections, which represent more than 10% of all SARS-CoV
infections, have been reported in many places, including Hong
Kong, Taiwan, Guangdong Province of China, and Singapore [4–
8]. Clinical and laboratory investigations have shown that the host
genetic background is an important factor that determines the
susceptibility to and pathogenicity of SARS infection. We have
demonstrated that genetic haplotypes associated with low serum
mannose-binding lectin (MBL) are also associated with SARS, and
our findings were confirmed by other independent studies [9,10].
Other susceptible genes, including chemokine (C–C motif) ligand
5( CCL5) [11], interferon gamma (IFN c) [12], 29–59 oligoadenylate
synthetase 1 (OAS) and myxovirus resistance 1 (MX1) [13], have
also been reported. The involvement of the major histocompat-
ibility complex class I gene (HLA) [14–16] and the L-SIGN gene
(CLEC4M) [17–19] are still disputed.
Several reports have suggested that the nucleocapsid protein of
SARS-CoV, which is expressed at the early stage of viral infection
and detectable in the serum [20], is associated with severe
pulmonary inflammation by inducing massive pro-inflammatory
cytokine production [21–23]. In an effort to elucidate this
mechanism, human cellular proteins that interact with the
nucleocapsid protein were screened by a yeast two-hybrid assay
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[24], cytochrome p450 subfamily 4F polypeptide 3 (CYP4F3,
Gene ID 4051, GenBank ID NG_007964.1) and alpha-2-HS-
glycoprotein (AHSG, Gene ID 197, GenBank ID NG_011436.1)
were found to interact with the nucleocapsid protein of SARS-
CoV (Unpublished data).
AHSG is required for macrophage deactivation by endogenous
cations. Low serum AHSG levels may cause the uncontrolled
production of proinflammatory cytokines [25,26]. Mice deficient
in AHSG showed hypersensitivity to LPS-induced inflammation
[27]. Cytochrome P450 Family 3A (CYP4F3A) is an v-oxidase
that inactivates the potent inflammatory factor Leukotriene B4
(LTB4) in human neutrophils and the liver [28]. LTB4 is likely a
major determining factor in tissue damage because it can amplify
the inflammatory reaction by recruiting leukocytes and inducing
their degranulation, which makes the removal of excess LTB4
important for the prevention of immunologic damage [29].
Considering that CYP4F3 and AHSG are involved in innate
immunity and inflammatory processes, we investigated whether
single-nucleotide polymorphisms (SNPs) in these genes were
associated with susceptibility to viral infection.
Results
SARS-Cov Nucleocapsid Protein Associates with AHSG
We previously noted in a yeast two-hybrid analysis that SARS-
Cov nucleocapsid protein associates with CYP4F3A, EEF1A and
AHSG (data not shown). To substantiate the interaction
between SARS-Cov N and AHSG, human serum was incubated
with GST or GST-N fusion proteins. The adsorbates were
analyzed by immunoblotting with anti-AHSG antibody. It was
demonstrated that AHSG binds to GST-N, but not GST
(Figure 1).
Study Participants and Demographics
We obtained peripheral blood or serum samples from SARS
patients who were diagnosed by WHO standards from two
different cities in China. Of the SARS patients, 67 were from the
Eighth People’s Hospital in southern China City, Guangzhou, and
624 were from Xiaotangshan Hospital (a hospital temporarily set
up to fight SARS in Beijing, China) or Ditan Hospital (Beijing,
China). All of the SARS samples were collected during the 2003
SARS epidemic. Analysis by ELISA and IFA confirmed all SARS
patients to be seropositive for anti-SARS antibodies, and the
specificity of the ELISA assay was higher than 99% [20,30,31].
For comparison, we obtained two groups of control samples from
Guangzhou (192 people) and Beijing (791 people). The Guangz-
hou control samples were collected during the 2003 SARS
epidemic while the Beijing control samples were collected after the
epidemic. All samples were collected from people who had never
developed SARS. To assess the influence of the exposure, blood
samples from health care workers (HCW) that worked in SARS
wards in the Second Affiliated Hospital of Senyaxian Medical
School in 2003 were obtained. Of these samples, 40 were from
HCW who developed SARS during the course of hospital duty
and 122 were from health care workers free of the disease. DNA
was extracted from all the samples selected. All cases and controls
were Han Chinese. We selected enough samples to perform three
progressive case-control studies.
Chi-square tests were carried out to evaluate whether the cases
and controls of the three studies were matched. We found that the
cases and controls from Beijing were well matched for sex and age,
while there were more females in the case cohort of the
Guangzhou non-HCW population. Most of the HCW population
was composed of female nurses between the ages of 16 and 30
(Table 1).
AHSG SNPs and SARS Development
We downloaded the SNP genotype data for CHB+JPT (version
2) from the HapMap database and built a linkage disequilibrium
(LD) map of AHSG with the Haploview software (version 4.0). The
pairwise tagging algorithm implemented in the Tagger program of
Haploview (r
2 threshold was 0.8) was used to select the tag SNPs
for assessment. SNPs that were reported to affect the AHSG level
or that had been associated with other diseases were also selected.
Finally, we chose to genotype rs2248690 (59-flanking region),
rs2077119 (59-flanking region), rs4917 (exon 6), rs2593813 (intron
1) and rs4918 (exon 7) in the AHSG gene. The genotyping and
statistical results are presented in Table S1 and Table S2 under
the dominant and additive models, respectively. The genotyping
and statistical analyses of the Guangzhou non-HCW population
revealed that two tag SNPs were associated with SARS. The
rs2248690 TT/AT genotype was more associated with increased
susceptibility to SARS than the AA genotype (OR=2.42; 95% CI,
1.30–4.51; Table 2 and Table S1). The TT/CT genotype of
rs4917 was associated with an increased possibility of developing
clinically apparent SARS (OR=1.84; 95% CI, 1.02–3.34;
Table 3 and Table S1). In the validation study (Beijing
population), only the rs2248690 polymorphism was significantly
associated with SARS development (relative to the TT/AT
genotype, 1.63; 95% CI, 1.30–2.04; Table 2 and Table S1).
Because the Beijing and Guangzhou sample groups had
homogenous demographic and genetic parameters (Han Chinese),
a joint analysis was performed. The combined analysis of the two
studies under the dominant model is presented in Table S3. After
combining data from the two cohorts, the TT/AT genotype of
rs2248690 had a frequency of 27.5% in the control population and
a significantly higher frequency of 39.1% in the SARS patients
(OR=1.70; 95% CI, 1.37–2.09; Table 2 and Table S3). After
adjusting for sex and age, a non-significant association was
observed between rs4917 and SARS susceptibility (OR=1.22;
95% CI, 1.02–1.54; P=0.08). Because rs4917 and rs2248690 are
in high linkage disequilibrium (0.62), the association between
rs4917 and SARS can be easily understood. A logistic regression
analysis was applied to adjust the linkage between rs4917 and
rs2248690. The result showed that rs2248690 was associated with
SARS development (OR=1.58; 95% CI, 1.16–2.17; p=0.004),
Figure 1. The nucleocapsid protein associates with serum
AHSG. Human serum (100 ml) was incubated with agarose beads
conjugated to GST-N protein or GST at 4uC for 2 h. The beads were
washed three times with PBS supplemented with 0.1% NP40. The
bound proteins were subjected to SDS-PAGE followed by immunoblot
with anti-AHSG antibody.
doi:10.1371/journal.pone.0023730.g001
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the influence of the exposure factor to SARS infection and risk,
cases and controls from the HCW population were genotyped at
rs2248690. Though the P-value is higher than 0.05, the
distribution of different genotypes between the HCW cases and
HCW controls is similar to the distribution between the non-HCW
cases and non-HCW controls with a difference of approximately
10%. The statistical analysis of the rs2248690 genotype data from
all cases and HCW controls confirmed this finding (OR=1.68;
95% CI, 1.38–2.06; Table 4). We tested the deviation from the
Hardy-Weinberg equilibrium in both cases and controls, within
each cohort and within the overall study population; we found that
there was no statistically significant deviation from equilibrium for
any SNP.
Based on these results, we conclude that the TT/AT genotype of
rs2248690 is associated with the increased likelihood of developing
SARS, while the AA genotype is associated with protection against
SARS.
rs2248690 is associated with AHSG serum concentration
AHSG is a serum protein, and it has been reported that there is an
association between AHSG polymorphisms (rs4917 and rs4918) and
AHSG serum concentration levels [32,33]. However, no convincing
multivariate analysis has been performed to identify the most
associated variants. To uncover potential functional changes
associated with the AHSG rs2248690 polymorphism, 192 healthy
subjects from Beijing were genotyped, and their AHSG serum
concentrations were determined. As expected, there was an
association between the rs2248690 genotype and the AHSG serum
concentrations (Table 5). The order of the average AHSG serum
c o n c e n t r a t i o n sw a sa sf o l l o w s :2799AA .2799AT .2799TT.
Consistently, rs4917 and rs4918 were associated with different serum
levels of AHSG. Furthermore, a stepwise regression analysis clearly
showed that rs2248690 was an independent contributor to the
variability in AHSG serum concentration (Table 5). These results
show that LD with rs2248690 causes the association of rs4917 with
AHSG serum concentration.
Because rs2248690 is located in the promoter region of the
AHSG gene (2799 bp upstream of the transcription start site),
various alleles of this SNP may yield phenotypic differences in
AHSG transcription levels. It has been reported that the A allele of
rs2248690 has a reduced binding affinity for transcription factor
AP1 [34], which is a repressor of AHSG expression [35,36]. We
observed allele-associated differences in the AHSG promoter’s
transcriptional activity in two different cell lines using a luciferase
assay. The sequence that contained 2799T, which is overrepre-
sented in SARS patients, showed significantly lower promoter
activity (Figure 2).
Table 2. The association results for rs2248690 in two independent samples and the combined sample.
Cohort and Group Genotype Allele
AA (%) AT (%) TT (%) OR
a (95% CI) P
a A (%) T (%) OR
b (95% CI) P
b
GZ Cohort Control 145 (75.52) 46 (23.96) 1 (0.52) 2.42 (1.30–4.51) 0.005 336 (87.50) 48 (12.50) 1.93 (1.16–3.22) 0.016
(Non-HCW) SARS 40 (59.70) 25 (37.31) 2 (2.99) 105 (78.36) 29 (21.64)
BJ Cohort Control 545 (71.71) 191 (25.13) 24 (3.16) 1.63 (1.30–2.04) ,0.001 1281 (84.28) 239 (15.72) 1.45 (1.20–1.77) ,0.001
SARS 369 (60.99) 214 (35.37) 22 (3.64) 952 (78.68) 258 (21.32)
Combined Control 690 (72.48) 237 (24.89) 25 (2.63) 1.69 (1.37–2.09) ,0.001 1617 (84.93) 287 (15.07) 1.53 (1.28–1.83) ,0.001
SARS 409 (60.86) 239 (35.57) 24 (3.57) 1057 (78.65) 287 (21.35)
CI, confidence interval; BJ, Beijing; GZ, Guangzhou.
a. Case vs. Control. A combined group of the minor-allele homozygotes and heterozygotes was compared with the major-allele homozygotes group ((AT+TT) vs. AA);
multivariate unconditional logistic regression was used.
b. Case vs. Control. The frequency of the A allele was compared to the frequency of the T allele; the CMH test was used.
doi:10.1371/journal.pone.0023730.t002
Table 1. The Demographic Characteristics of the SARS Patients and Controls.
Guangzhou Non-HCW Population Beijing Population HCW Population
SARS patients Controls P SARS patients Controls P SARS patients Controls P
(N=67) No. (%) (N=192) No. (%) (N=624) No. (%) (N=791) No. (%) (N=40) No. (%) (N=122) No. (%)
Sex
Male 29 (43.28) 99 (51.56) 0.24 312 (50.00) 412 (52.09) 0.44 3 (7.50) 12 (9.84) 0.66
Female 38 (56.72) 93 (48.44) 312 (50.00) 379 (47.91) 37 (92.50) 110 (90.16)
Age, y
16–30 21 (31.34) 57 (29.69) 0.78 253 (40.54) 339 (42.86) 0.26 29 (72.50) 85 (69.67) 0.96
31–40 23 (34.33) 58 (30.21) 152 (24.36) 163 (20.61) 9 (22.50) 31 (25.41)
41–50 13 (19.40) 49 (25.52) 131 (21.00) 159 (20.10) 1 (2.50) 4 (3.28)
.50 10 (14.93) 28 (14.58) 88 (14.10) 130 (16.43) 1 (2.50) 2 (1.64)
P was calculated using the x
2 test.
doi:10.1371/journal.pone.0023730.t001
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We also built an LD map of CYP4F3 and selected five tag SNPs
for assessment (Table S1, Table S2 and Table S3). In the non-
HCW Guangzhou population, the rs3794987 GG/AG genotype
was associated with an increased susceptibility to SARS
(OR=2.01; 95% CI, 1.10–3.68). However, the results of this
association were not replicated in the Beijing population. The
combined analysis of the two studies does not show any association
of the CYP4F3 SNPs analyzed with SARS susceptibility.
Discussion
After the interaction between AHSG and the SARS-CoV
nucleocapsid protein was identified and validated, we chose AHSG
as a candidate gene in subsequent case-control analyses. We found
an association between one SNP in AHSG (rs2248690) and the
development of SARS in two separate case-control studies as well
as in the combined analysis of both studies after adjusting for age
and sex. Considering the exposure factor, the intercomparison of
the HCW-controls and the other cases validated the association we
observed between rs2248690 and SARS disease because the
HCW-controls, who had worked in SARS wards, were exposed to
SARS-CoV at least as much as the other cases. Additionally, this
polymorphism, which was located in the promoter of AHSG,
affects AHSG serum levels by altering the transcriptional activity.
The genotype that conferred protection against SARS, rs2248690
AA, is associated with higher AHSG serum levels.
Our case-control studies included 1833 individuals and revealed
a significant association between rs2248690 and the SARS disease.
More specifically, individuals with the AA genotype have a 41%
lower risk of developing SARS than those with the TT/AT
genotype. The rs2248690 SNP is located in the 59 flanking region
of AHSG at position 2799 within the promoter region. We have
shown that this variant affects AHSG serum levels by altering
transcriptional activity. Other SNPs in the AHSG, such as rs4917
and rs4918, have also been shown to be associated with AHSG
serum levels and diseases affected by AHSG serum levels [33]. In
this study, we demonstrated that rs2248690 is the dominant factor
affecting AHSG concentration.
AHSG is a circulating negative inflammatory acute-phase
glycoprotein. The pathophysiological sequence of infection is
mediated by macrophage-derived pro-inflammatory cytokines.
The current literature suggests that the availability of AHSG to
macrophages is critical in regulating the innate immune response
in tissue injury and infection because AHSG is required for
macrophage deactivation by endogenous cations [37]. Decreased
levels of human fetuin have been observed in patients with acute
lymphocytic Hodgkin’s and non-Hodgkin’s lymphomas, rheuma-
Table 3. The association results for rs4917 in two independent samples and the combined sample.
Cohort and Group Genotype Allele
CC (%) CT (%) TT (%) OR
a (95% CI) P
a C (%) T (%) OR
b (95% CI) P
b
GZ Cohort Control 98 (56.65) 69 (39.88) 6 (3.47) 1.84 (1.02–3.34) 0.04 265 (76.59) 81 (23.41) 1.49 (0.95–2.33) 0.10
(Non-HCW) SARS 28 (43.75) 32 (50.00) 4 (6.25) 88 (68.75) 40 (31.25)
BJ Cohort Control 391 (53.64) 282 (38.68) 56 (7.68) 1.21 (0.98–1.51) 0.08 1064 (72.98) 394 (27.02) 1.12 (0.95–1.33) 0.18
SARS 299 (48.07) 281 (45.18) 42 (6.75) 879 (70.66) 365 (29.34)
Combined Control 489 (54.21) 351 (38.91) 62 (6.87) 1.22 (1.02–1.54) 0.08 1329 (73.67) 475 (26.33) 1.17 (1.00–1.37) 0.05
SARS 327 (47.67) 313 (45.63) 46 (6.71) 967 (70.48) 405 (29.52)
CI, confidence interval; BJ, Beijing; GZ, Guangzhou; HCW, health care workers.
a. Case vs. Control. A combined group of the minor-allele homozygotes and heterozygotes was compared with the major-allele homozygotes group ((CT+TT) vs. CC);
multivariate unconditional logistic regression was used.
b. Case vs. Control. The frequency of the C allele was compared to the frequency of the T allele; the CMH test was used.
Table 4. Evaluation of the Exposure Factor.
Cohorts compared Genotype No. Cases (%) No. Controls (%)
Crude OR
a
(95% CI) P
a Value
Adjusted OR
b
(95% CI) P
b Value
HCW Cases vs. HCW ControlsAA 25 (62.50) 88 (72.10) 1[Reference] 1[Reference]
TT/AT 15 (37.50) 34 (27.90) 1.55 (0.73–3.30) 0.32 1.54 (0.72–3.28) 0.27
GZ Cases vs. HCW Controls AA 65 (60.75) 88 (72.13) 1[Reference] 1[Reference]
TT/AT 42 (39.25) 34 (27.87) 1.67 (0.96–2.91) 0.09 1.73 (0.94–3.18) 0.08
All Cases vs. HCW Controls AA 434 (60.96) 88 (72.13) 1[Reference] 1[Reference]
TT/AT 278 (39.04) 34 (27.87) 1.66 (1.09–2.53) 0.02 1.58 (1.00–2.47) 0.05
All Cases vs. All controls AA 434 (60.96) 778 (72.44) 1[Reference] 1[Reference]
TT/AT 278 (39.04) 296 (27.56) 1.68 (1.38–2.06) ,0.001 1.68 (1.38–2.06) ,0.001
Abbreviations used: CI, confidence interval; OR, odds ratio; HCW, health care workers; GZ, Guangzhou. All OR and P values are from the reference group but against the
other category.
a Values calculated using the CMH test.
b Values adjusted for age and sex using the multivariate unconditional logistic regression.
doi:10.1371/journal.pone.0023730.t004
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Under conditions where macrophage-associated fetuin levels are
decreased, macrophage deactivation by endogenous counter-
regulators may be impaired, leading to the uncontrolled
overproduction of pro-inflammatory cytokines [29,38]. A recent
work showed that mice deficient in AHSG are hypersensitive to
LPS-induced inflammation [27]. Because the development of
SARS is always associated with a severe inflammatory reaction,
low AHSG serum levels could result in severe symptoms after a
SARS-CoV infection. Considering that there might be many
asymptomatic SARS-CoV infections in the control group, it is
plausible that relatively higher serum concentrations of AHSG can
orchestrate an unimpaired counter-regulation between macro-
phage deactivation and endogenous pro-inflammatory cytokines.
Therefore, viruses can be cleared without severe inflammation and
obvious symptoms. However, we observed that AHSG interacts
with the SARS-CoV nucleocapsid protein (Figure 1), which may
induce massive pro-inflammatory cytokine production upon
infection [21]. AHSG may neutralize the pro-inflammatory effect
of the SARS nucleocapsid protein because AHSG is so abundant
in the serum (0.2–0.55 mg/ml). Considering that AHSG is a
circulating glycoprotein synthesized in human liver tissue and the
nucleocapsid protein is ‘‘wrapped’’ by membrane proteins in the
SARS-CoV virion, interactions between AHSG and the nucleo-
capsid protein are less likely to affect the viral infectivity and
replication of the SARS-CoV.
To our knowledge, this is the first study reporting an association
of AHSG polymorphisms with SARS. Individuals with polymor-
phisms that contribute to high concentrations of AHSG may be
less likely to develop SARS. These findings improve our
understanding of SARS pathogenesis and provide a genetic basis
for SARS prognosis. Future studies should further investigate the
mechanisms of AHSG-based resistance to SARS and other
infectious diseases.
Materials and Methods
Ethics Statement
Written, informed consent was obtained from all of the
participants or their guardians; genetic analysis was covered in
the consent. This study was performed with the approval of the
Ethics Committees of all the hospitals from which samples were
obtained and it was also approved by the the Ethics Committees of
Chinese National Human Genome Center, Beijing Institute of
Table 5. Variants Affecting AHSG Serum Levels.
Variables b TP
a
rs2248690 20.737 214.336 0.0001
rs4917 0.014 0.209 0.84
rs4918 20.011 20.162 0.87
Sex 20.057 21.11 0.27
Age 0.002 0.046 0.96
rs2248690 Genotype N (%) AHSG concentration (mean ± S.E.M) mg/ml P
(ANOVA)
AA 142 (74.0%) 583633
AT 45 (23.4%) 541625 ,0.001
TT 5 (2.6%) 492628
aStepwise multivariate regression analysis.
doi:10.1371/journal.pone.0023730.t005
Figure 2. The rs2248690(2799A/T) polymorphism regulates AHSG promoter activity. Left, a schematic of two reporter gene constructs.
Right, luciferase expression of the constructs in different cells. Each value represents the mean 6 S.D. of five independent experiments that were
performed in triplicate. *, P,0.05.
doi:10.1371/journal.pone.0023730.g002
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was conducted according to the principles of the Declaration of
Helsinki.
Study Participants
The first case-control study was performed to evaluate potential
associations between AHSG and CYP4F3 polymorphisms with
SARS. The second case-control study was performed to confirm
the findings from the first study. The HCW case-control study was
used to evaluate the influence of the exposure rate and to
reconfirm the findings of positively associated SNPs. The
association of the AHSG genotype and AHSG serum concentra-
tions was evaluated in 192 healthy Beijing Han Chinese.
Case-Control Study 1
Serum samples from 67 SARS patients diagnosed by WHO
standards were collected from the Eighth People’s Hospital of
Guangzhou in 2003. Analysis by enzyme-linked immunosorbent
assay (ELISA) and immunofluorescent assay (IFA) confirmed that
all of the SARS patients were seropositive for SARS antibodies.
The specificity of the ELISA assay was higher than 99%
[20,30,31]. Serum samples from 192 age-, sex-, and ethnicity-
matched controls were collected from healthy people in Guangz-
hou during the same period. All cases and controls were Han
Chinese.
Case-Control Study 2
Blood samples from 624 patients diagnosed by WHO
standards were collected from Xiaotangshan Hospital (a hospital
temporarily set up to fight SARS in Beijing, China) and Ditan
Hospital (Beijing, China) during the SARS epidemic in 2003. All
SARS patients selected were confirmed to be seropositive by both
an enzyme-linked immunosorbent assay (ELISA) and an
immunofluorescent assay (IFA) [20,30,31]. Information regarding
sex, ethnic status, and age at SARS diagnosis was recorded. A
total of 791 age-, sex-, and ethnicity-matched adults were
recruited as control subjects after the 2003 SARS epidemic,
and none of these control subjects ever developed SARS
(Table 1). Of these samples, 352 infected patients (from
Xiaotangshan Hospital) and 410 controls were from the BPRC
(Beijing Proteome Research Center) of China and were
previously employed in a study that showed no association
between CLEC4M homozygosity and protection against SARS
coronavirus [18]. All cases and controls were Han Chinese. The
remaining 272 samples of SARS patients were collected from the
Ditan Hospital.
HCW Population Case-Control Study
Blood samples were obtained from 40 health care workers that
developed SARS during the course of hospital duty and 122 health
care workers who had worked in SARS wards but remained free of
the disease. All of these HCW workers worked in SARS wards in
the Second Affiliated Hospital of Senyaxian Medical School in
2003. Information regarding sex and age was recorded. The
HCW cases and controls were Han Chinese.
rs2248690 Genotype and AHSG Serum Concentration
study
Blood samples from 192 healthy Beijing Chinese were collected
from the 307 Hospital of PLA (People’s Liberation Army) in
Beijing, and sera were collected. Serum AHSG levels were
assessed by ELISA, and the rs2248690 loci were genotyped as
described below.
DNA Isolation
Peripheral blood samples were obtained from Guangzhou
HCW and Beijing cohorts. A total of 200 ml of each blood sample
was mixed and incubated with 16RBC lysis buffer (1.5 M
ammonium chloride, 100 mM potassium bicarbonate and
10 mM EDTA). Subsequently, the lymphocytes were obtained
by centrifugation. Serum samples were obtained from the
Guangzhou non-HCW cases and controls. Genomic DNA from
all the peripheral blood leukocytes and plasma samples was
extracted using the QIAamp DNA Blood Mini Kit (Qiagen,
Valencia, CA) and stored at 220uC. The resulting DNA was
quantified using a standard spectrophotometric reading on a DU
650 spectrophotometer (Beckman Coulter,Fullerton, CA). Each
sample was diluted to a final concentration of 10 ng/ml.
Selection of SNPs
For the association study, we downloaded the SNP genotype
data for CHB+JPT (version 2) from the HapMap database and
built LD maps of these two genes with the Haploview software. A
pairwise tagging algorithm implemented in the Tagger program of
Haploview (with an r
2 threshold of 0.8) was used to select the tag
SNPs. SNPs that were reported to affect AHSG/CYP4F3 levels or
had been associated with other diseases were also selected. Finally,
we chose to genotype rs2248690 (59-flanking region), rs2077119
(59-flanking region), rs4917 (exon 6), rs2593813 (intron 1), and
rs4918 (exon 7) in the AHSG gene. The CYP4F3 gene has more
than 30 SNPs in three linkage disequilibrium blocks. We chose
rs3794987 (59-flanking region), rs1159776 (59-flanking region),
rs4646519 (intron 11), and rs1290625 (intron 2) for genotyping.
Genotyping
Genotyping was completed using the SNPstream ultra-high
throughput genotyping system (Beckman Coulter, Fullerton, CA)
according to the manufacturer’s instructions. Briefly, the method
combines solution-phase multiplex single nucleotide extension
(SNE) with a solid-phase sorting of labeled SNE primers by
hybridization to a chip that contains 384 464 arrays of 12
oligonucleotide tags and 4 oligonucleotides for positive and
negative controls. Each SNE primer contained 1 of the 20
oligonucleotide tags at its 59 end, and the SNE reactions were
performed in 12-plex. The microarray plate was imaged using a
SNP scope reader (Beckman Coulter, Fullerton, CA). The two-
color system allowed the detection of the SNP by comparing the
signals from the two fluorescent dyes. The image signals were
subsequently transferred to genotyping software that translated the
images of the arrays into genotype calls. The error rate (0–1.2%)
was determined by DNA sequencing (3730, Applied Biosystem
Inc) for 10% of the SNPs examined in the present study.
Statistical Analysis
Chi-square tests were used to compare the genotypic frequen-
cies and demographic distributions between the cases and controls.
The exact test was applied to evaluate whether the population was
in Hardy–Weinberg equilibrium by the Markov chain method; P-
values less than 0.05 were considered statistically significant. The
tag SNPs were chosen on a pairwise basis, and the linkage
disequilibrium (LD) calculation was performed on a confidence
interval (CI) basis using the Haploview 4.0 software.
Fisher’s exact test and multivariate unconditional logistic
regression were used to estimate the crude and adjusted odds
ratios for each sex and age category. The odds ratio and a 95% CI
were used to measure the strength of association in the genetic risk
association study. The additive and dominant models were used
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and separated into three categories with the homozygous major
allele genotype chosen as the reference group. For the dominant
model, each SNP was modeled as a dichotomous variable with the
homozygous major allele genotype as the reference group and the
other two genotypes combined into one category.
ANOVA and stepwise multivariate regression analyses were
performed to identify the SNPs associated with AHSG serum
levels. These statistical analyses were performed using SAS
(version 8.0).
Serum AHSG assay
Serum AHSG concentrations were measured in 192 subjects by
ELISA. Briefly, the sera were diluted 10,000-fold and pipetted into
the wells of a microtiter plate whose surfaces were coated with
polyclonal anti-human AHSG antibodies (R&D). After incubation,
horseradish peroxidase (HRP) -conjugated polyclonal anti-human
AHSG antibodies were added to the wells. Following the
incubation and washing steps, the absorbance was measured
using an automated plate reader at 450 nm. The concentrations of
the diluted sera were read from the standard curve of human
AHSG, and the concentrations of the experimental samples were
calculated. All samples were measured in parallel and in duplicate.
The intra- and inter-assay coefficients of variations were below
10%. The statistical analyses were done using ANOVA.
Promoter assays
Two reporter plasmids encompassing 21091 to +22 bp of the
human AHSG promoter were generated by PCR from two
genomic DNA samples with either 2799A OR -799T, using the
primers P1: 59-cgcagatctGGTCTCCATGAGAGGGCTTC-39
and P2: 59-cgcaagcttCAGGCGTGCAGGTGGTTG-39, respec-
tively. The PCR product was digested with BglII and HindIII and
ligated into a pGL3-basic promoter-probing vector (Promega)
containing the firefly luciferase gene as a reporter. The constructs
were sequenced to ensure correct cloning.
HepG2 and HL7702 cells were seeded at 1610
5 cells per well,
respectively, in 12-well plates and transfected with pGL3-basic (a
promoterless control) or pGL3-basic containing a particular allele
of the AHSG promoter. The pRL-SV40 plasmid (Promega) was
cotransfected as a normalizing control. All transfections were
carried out in triplicate. At 24 h post-incubation, the cells were
collected and analyzed for luciferase activity using the Dual-
Luciferase Reporter Assay System (Promega). The data shown
represent three independent experiments performed in triplicate.
The statistical analyses were performed using the Student’s t-test.
Protein-binding assays
For the GST pull-down experiments, human serum were
incubated for 2 h at 4uC with 5 mg of purified GST or GST fusion
proteins bound to glutathione beads (GE Healthcare, Little
Chalfont, Buckinghamshire, UK). The adsorbates were washed
with lysis buffer and subjected to SDS-PAGE and immunoblot
analysis. Purified AHSG protein was included as a loading control.
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